We offer our registered users tailored information, free online courses and exclusive content.
Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?
... or you lost your password?
English
This live educational conference will look at available evidence on specific and relevant topics related to cardiovascular disease. Discussion will focus on increased sympathetic activity in the pathogenesis of hypertension-related heightened cardiovascular risk and the need to consider high heart rate as a target for treatment. The role of combination treatment in hypertension and recent novelties in the availability of fixed dose formulations will also be addressed. Treating the main hypertension - related clinical conditions, including acute coronary syndrome and heart failure, will also be discussed. Another major topic of interest will be to the optimal timeline for treating diabetic patients with beta-blockers and if there are differences among different molecules of this class.
Time will also be dedicated to interactive clinical case discussions which will translate results from controlled clinical trials and guidelines into applications for daily clinical practice.
By attending this live educational programme, participants will be able to:
• Highlight sympathetic nervous system over activity as a pathogenetic mechanism in hypertensive-related cardiovascular risk and discuss if this parameter can be considered a target in antihypertensive treatment
• Discuss the role of fixed dose combinations in the treatment of hypertension and address the therapeutic relevance of the new fixed dose combination beta-blocker/calcium antagonist
• Identify the best practice according to guidelines for treating hypertensive patients with coronary artery disease
• Manage the complex transition from hypertension to heart failure and discuss the possible beneficial effect of pharmacological
treatment
• Select the best beta-blocker compound when treating patients with diabetes
An application will be made to the European Board for Accreditation in Cardiology (EBAC) for CME accreditation of the “6th EMEA forum on cardiovascular risks”, to be held on 18 November 2017 in Lisbon, Portugal.
Saturday, 18 November 2017
08.20 Opening and introduction
G. Mancia (Italy)
Session I
08.30 L1 Sympathetic nervous system and cardiovascular risk VIDEO LECTURE
G. Mancia (Italy)
08.50 L2 Should increased heart rate be considered a target in cardiovascular treatment? VIDEO LECTURE
H. A.J. Struijker-Boudier (The Netherlands)
09.10 L3 New possibilities for the fixed-dose combination treatment in hypertension VIDEO LECTURE
S. Taddei (Italy)
09.30 Panel discussion
09.50 Coffee break
Session II
10.10 L4 Best practice in the management of stable chronic angina VIDEO LECTURE
B. Tomlinson (Hong Kong)
10.30 L5 From hypertension to heart failure: prevention strategies VIDEO LECTURE
E. Erdmann (Germany)
10.50 L6 Use of betablockers in diabetes VIDEO LECTURE
G. Grassi (Italy)
11.10 Panel discussion
Session III
11.30 Working groups
This session includes two different parallel workshops, each lasting 1 hour. Participants will be divided into groups and will attend both workshops in rotation. By the end of the session each participant will have attended both workshops.
WG1 The role of beta-blockers in hypertensive patients
Presenter: H. A.J. Struijker-Boudier (The Netherlands)
Discussant: B. Tomlinson (Hong Kong)
WG2 How to optimize treatment in patients with heart failure
Presenter: E. Erdmann (Germany)
Discussant: S. Taddei (Italy)
13.30 Take home messages from the working groups and wrap up
13.50 Closing remarks
G. Mancia (Italy)
14.00 End of the workshop
Closing lunch
EXCEMED - Excellence in Medical Education
The registration fee is 150€ and includes:
• Access to scientific sessions
• Educational materials
• Certificate of attendance
• Coffee break and luncheons
Dinners are not included.
